Meeting
2020 ASCO Virtual Scientific Program
Effects of GC4419 (avasopasem manganese) on chronic kidney disease in head and neck cancer patients treated with radiation and cisplatin.
Authors
Emily J. Steinbach
University of Iowa, Iowa City, IA
Emily J. Steinbach , Varun Monga , Muhammad Furqan , Douglas Earl Laux , Diana Zepeda-Orozco , Jennifer G. Jetton , Deborah Saunders , Neal Dunlap , Amarinthia Curtis , Robert Fairbanks , Sarah Bell , Carryn M. Anderson , Robert Alan Beardsley , Jon Holmlund , Douglas Spitz , Bryan G. Allen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Late and Long-Term Adverse Effects
Clinical Trial Registration Number
NCT02508389
Citation
J Clin Oncol 38: 2020 (suppl; abstr 12071)
DOI
10.1200/JCO.2020.38.15_suppl.12071
Abstract #
12071
Poster Bd #
359
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
One-year reductions in cisplatin-related chronic kidney disease (CKD) in patients with head and neck (HNC) cancer treated with avasopasem manganese: A prespecified analysis from the phase 3 ROMAN trial.
First Author: Bryan G. Allen
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC).
First Author: Shilpa Gupta
Poster
2023 ASCO Annual Meeting
XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
First Author: Robert L. Ferris
Poster
2020 ASCO Virtual Scientific Program
Results of a randomized, open-label, multicenter trial to assess the safety, dose, and schedule ofRRx-001(001) in reducing incidence, severity and duration of severe oral mucositis (SOM) inpatients receiving concomitant chemoradiation (CRT) for advanced head and neck cancer (HNC).
First Author: Marcelo Raul Bonomi